EUROPE DRY EYE DISEASE MARKET FORECAST 2023-2032
SCOPE OF THE REPORT
Europe Dry Eye Disease Market by Type (OTC, Prescription) Market by Product (Anti-inflammatory Drugs (Cyclosporine, Corticosteroid, Other Anti-inflammatory Drugs), Artificial Tears, Punctal Plugs, Secretagogues, Other Products) Market by Distribution Channel (Hospital Pharmacies, Independent Pharmacies and Drugstores, Online Pharmacies) by Geography
REPORTS » HEALTHCARE » MEDICAL DEVICES » EUROPE DRY EYE DISEASE MARKET FORECAST 2023-2032
MARKET OVERVIEW
The Europe dry eye disease market growth is anticipated to progress at a CAGR of 4.79% during the forecast period, 2023-2032, and is predicted to garner a revenue of $2569.11 million by 2032.
The dry eye disease market growth in Europe is accredited to the increasing glaucoma incidences, the growing market consolidation, the surging awareness about the dry eye disease condition, and the rising aging population. Also, the region has robust healthcare with heavy investments by both private and government players. However, the Europe dry eye disease market growth is hindered by the availability of alternative treatments and side effects caused by eye drops.
To Know More About This Report, Request a Free Sample Copy
The Europe dry eye disease market growth evaluation includes the analysis of Italy, the United Kingdom, Poland, Spain, France, Germany, Belgium, and Rest of Europe. In the United Kingdom, the growing awareness about dry eye disease and the rising government support are estimated to drive the analyzed market’s growth. Also, the National Health Service (NHS) offers eye screening programs alongside helpline numbers for dry eye treatment. In addition, the UK conducts different types of research on dry eye disease, which contributes to overall growth prospects. Whereas, in France, the increasing number of treatments and the rising patient population fuel the market growth.
The Europe dry eye disease market segmentation includes distribution channel, type, and product. The distribution channel segment includes hospital pharmacies, online pharmacies, and independent pharmacies and drugstores.
Retail pharmacies are independent pharmacies with a state license to offer drugs to the general public. Over-the-counter (OTC) medications are among the essential components of this distribution channel. As a result, people are increasingly using retail pharmacies as a one-stop shop for acquiring OTC products. Additionally, such medications’ cost is lower than hospital pharmacies’ medications. This serves as an added incentive for consumers to choose independent pharmacies.
Further, the retail pharmacy sector facilitates an omnichannel, convenient pharmacy experience. It includes home delivery. Also, there is a growing scope for in-home pharmacy experience, with consumers becoming more convenience-focused and experimenting with digital-first pharmacy entrants, particularly post-COVID-19. Besides, a large number of drugstores and small pharmacies are transitioning from conventional models to tech-enabled models and from in-person pickup to delivery. Such aspects are projected to drive independent pharmacies’ growth.
Furthermore, the growing prevalence of dry eye disease leads to a rising number of hospital visits, thereby promoting the sales of dry eye disease drugs through hospital pharmacies. Generally, pharmacists collaborate with other pharmacies to buy suppliers. However, in Eastern Europe, wholesalers are the primary supplier of pharmaceuticals. Whereas in Western Europe, hospital pharmacists frequently buy their supplies directly from businesses.
Additionally, unit-dose supply is typical in a few nations where distribution is largely centralized. Besides, pharmacies also offer services to outpatients, with a third of hospitals utilizing barcode technology for stock control and manual item selection. Large hospitals have more automation than smaller hospitals.
Some of the eminent market players in the Europe dry eye disease market are Santen Pharmaceutical Co Ltd, Novartis AG, Otsuka Pharmaceutical Co Ltd, OASIS Medical, etc.
Novartis AG is a Swiss-American multinational pharmaceutical company that provides products for gene, cell, cancer, metabolic, and cardio therapies. The product portfolio includes biosimilars, generic medicines, vision care products, ophthalmic pharmaceuticals, etc. The company operates across the Middle East & Africa, the Americas, Europe, and Asia-Pacific, with headquarters in Basel, Switzerland.
One of its key products, Xiidra® (lifitegrast ophthalmic solution) 5%, is the only prescription treatment approved to treat symptoms and signs of dry eyes by inhibiting inflammation caused by the disease.
REPORT SYNOPSIS
REPORT SCOPE | DETAILS |
---|---|
Market Forecast Years | 2023-2032 |
Base Year | 2022 |
Market Historical Years | 2018-2022 |
Forecast Units | Revenue ($ Million) |
Segments Analyzed | Distribution Channel, Product, Type |
Countries Analyzed | Italy, the United Kingdom, Poland, Spain, France, Germany, Belgium, and Rest of Europe |
Companies Analyzed | AFT Pharmaceuticals, Alcon, Allergan Plc (Acquired by AbbVie), Bausch Health Companies Inc, Johnson & Johnson, Lumenis, Novaliq GmbH, Novartis AG, OASIS Medical, Otsuka Pharmaceutical Co Ltd, Santen Pharmaceutical Co Ltd, Sentiss Pharma Private Limited, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, VISUfarma |
TABLE OF CONTENT
RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- SCOPE OF STUDY
- CRISIS SCENARIO ANALYSIS
- MAJOR MARKET FINDINGS
- AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
- COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
- ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
- EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS
MARKET DYNAMICS
- KEY DRIVERS
- INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
- LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
- GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
- KEY RESTRAINTS
- RISK OF SIDE EFFECTS
- SUBSTITUTE THERAPIES
- EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO
- KEY DRIVERS
KEY ANALYTICS
- PARENT MARKET ANALYSIS
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
- BUYERS POWER
- SUPPLIERS POWER
- SUBSTITUTION
- NEW ENTRANTS
- INDUSTRY RIVALRY
- GROWTH PROSPECT MAPPING
- MARKET MATURITY ANALYSIS
- MARKET CONCENTRATION ANALYSIS
- VALUE CHAIN ANALYSIS
- RESEARCH AND DEVELOPMENT
- MANUFACTURING
- DISTRIBUTORS
- POST-SALES MONITORING
MARKET BY TYPE
- OTC
- PRESCRIPTION
MARKET BY PRODUCT
- ANTI-INFLAMMATORY DRUGS
- CYCLOSPORINE
- CORTICOSTEROID
- OTHER ANTI-INFLAMMATORY DRUGS
- ARTIFICIAL TEARS
- PUNCTAL PLUGS
- SECRETAGOGUES
- OTHER PRODUCTS
- ANTI-INFLAMMATORY DRUGS
MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACIES
- INDEPENDENT PHARMACIES AND DRUGSTORES
- ONLINE PHARMACIES
GEOGRAPHICAL ANALYSIS
- EUROPE
- MARKET SIZE & ESTIMATES
- EUROPE DRY EYE DISEASE MARKET DRIVERS
- EUROPE DRY EYE DISEASE MARKET CHALLENGES
- EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
- KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET
- COUNTRY ANALYSIS
- UNITED KINGDOM
- UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
- GERMANY
- GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
- FRANCE
- FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
- ITALY
- ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
- BELGIUM
- BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
- SPAIN
- SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
- POLAND
- POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
- REST OF EUROPE
- REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
- UNITED KINGDOM
- EUROPE
COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
- MERGERS & ACQUISITIONS
- PRODUCT LAUNCHES & DEVELOPMENTS
- PARTNERSHIPS & AGREEMENTS
- BUSINESS EXPANSIONS & DIVESTITURES
- COMPANY PROFILES
- AFT PHARMACEUTICALS
- ALCON
- ALLERGAN PLC (ACQUIRED BY ABBVIE)
- BAUSCH HEALTH COMPANIES INC
- JOHNSON & JOHNSON
- LUMENIS
- NOVALIQ GMBH
- NOVARTIS AG
- OASIS MEDICAL
- OTSUKA PHARMACEUTICAL CO LTD
- SANTEN PHARMACEUTICAL CO LTD
- SENTISS PHARMA PRIVATE LIMITED
- SUN PHARMACEUTICAL INDUSTRIES LTD
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- VISUFARMA
- KEY STRATEGIC DEVELOPMENTS
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – DRY EYE DISEASE
TABLE 2: EUROPE DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: EUROPE DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 4: EUROPE DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: EUROPE DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 6: EUROPE DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: EUROPE DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 8: EUROPE DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: EUROPE DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 10: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 11: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 12: EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 13: KEY PLAYERS OPERATING IN EUROPE DRY EYE DISEASE MARKET
TABLE 14: LIST OF MERGERS & ACQUISITIONS
TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR EUROPE
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022
FIGURE 8: EUROPE DRY EYE DISEASE MARKET, BY OTC, 2023-2032 (IN $ MILLION)
FIGURE 9: EUROPE DRY EYE DISEASE MARKET, BY PRESCRIPTION, 2023-2032 (IN $ MILLION)
FIGURE 10: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2022
FIGURE 11: EUROPE DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)
FIGURE 12: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY ANTI-INFLAMMATORY DRUGS, IN 2022
FIGURE 13: EUROPE DRY EYE DISEASE MARKET, BY CYCLOSPORINE, 2023-2032 (IN $ MILLION)
FIGURE 14: EUROPE DRY EYE DISEASE MARKET, BY CORTICOSTEROID, 2023-2032 (IN $ MILLION)
FIGURE 15: EUROPE DRY EYE DISEASE MARKET, BY OTHER ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)
FIGURE 16: EUROPE DRY EYE DISEASE MARKET, BY ARTIFICIAL TEARS, 2023-2032 (IN $ MILLION)
FIGURE 17: EUROPE DRY EYE DISEASE MARKET, BY PUNCTAL PLUGS, 2023-2032 (IN $ MILLION)
FIGURE 18: EUROPE DRY EYE DISEASE MARKET, BY SECRETAGOGUES, 2023-2032 (IN $ MILLION)
FIGURE 19: EUROPE DRY EYE DISEASE MARKET, BY OTHER PRODUCTS, 2023-2032 (IN $ MILLION)
FIGURE 20: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022
FIGURE 21: EUROPE DRY EYE DISEASE MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)
FIGURE 22: EUROPE DRY EYE DISEASE MARKET, BY INDEPENDENT PHARMACIES AND DRUGSTORES, 2023-2032 (IN $ MILLION)
FIGURE 23: EUROPE DRY EYE DISEASE MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)
FIGURE 24: EUROPE DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
FIGURE 25: UNITED KINGDOM DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 26: GERMANY DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 27: FRANCE DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 28: ITALY DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 29: BELGIUM DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 30: SPAIN DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 31: POLAND DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 32: REST OF EUROPE DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FAQ’s
RELATED REPORTS
-
GLOBAL MULTIPLEX ASSAY MARKET FORECAST 2024-2032
-
GERMANY MULTIPLEX ASSAY MARKET FORECAST 2024-2032
-
INDIA MULTIPLEX ASSAY MARKET FORECAST 2024-2032
-
UNITED STATES MULTIPLEX ASSAY MARKET FORECAST 2024-2032
-
EUROPE PORTABLE AIR PURIFIER MARKET FORECAST 2024-2032
-
GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET FORECAST 2024-2032
-
GERMANY ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET FORECAST 2024-2032
-
INDIA ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET FORECAST 2024-2032
-
UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN HEALTHCARE MARKET FORECAST 2024-2032
-
GLOBAL TRANSPORT MEDIA MARKET FORECAST 2024-2032